Sanofi Consumer Healthcare CFO Narahari Naidu resigns

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

30 January 2026 00:00:00

Adani Ports

1417.65

(0.12%)

Asian Paints

2428.65

(0.49%)

Axis Bank

1370.25

(0.43%)

Bajaj Finance

930.55

(-0.48%)

Bajaj Finserv

1953.35

(0.28%)

Bharat Electro..

449.00

(1.01%)

Bharti Airtel

1968.10

(0.00%)

Eternal

273.70

(-0.55%)

HCL Technologi..

1694.45

(-1.55%)

HDFC Bank

929.35

(-0.67%)

Hind. Unilever

2373.65

(0.94%)

ICICI Bank

1355.05

(-2.10%)

Infosys

1640.45

(-1.04%)

Interglobe Avi..

4597.35

(-0.54%)

ITC

322.20

(1.11%)

Kotak Mah. Ban..

408.00

(-1.05%)

Larsen & Toubr..

3933.45

(0.03%)

M & M

3432.20

(1.38%)

Maruti Suzuki

14601.55

(0.70%)

NTPC

355.80

(-0.64%)

Power Grid Cor..

256.35

(-1.61%)

Reliance Indus..

1395.90

(0.29%)

SBI

1077.55

(1.23%)

Sun Pharma.Ind..

1595.00

(0.36%)

Tata Steel

193.10

(-4.57%)

TCS

3125.05

(-0.67%)

Tech Mahindra

1743.30

(-1.39%)

Titan Company

3977.45

(0.99%)

Trent

3785.60

(-0.98%)

UltraTech Cem.

12700.05

(-0.15%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Sanofi Consumer Healthcare CFO Narahari Naidu resigns	Share Back
(13 Oct 2025)
According to the company's regulatory filing, Naidu’s resignation will be effective from the close of business hours on 15 October 2025, which will be his last working day with the company. Sanofi Consumer Healthcare India officially demerged from Sanofi India on 1 June 2024 and now operates as an independent entity focused solely on the consumer healthcare segment. Its key product categories include allergy care, digestive wellness, pain relief, multivitamins, and herbal/traditional supplements, with flagship brands such as Allegra, DePURA, Avil, and Combiflam anchoring its portfolio. The company reported a 28% year-on-year rise in revenue to Rs 220.9 crore in Q2 2025, powered by export operations and successful product launches. On a sequential basis, the company’s revenue rose 27.5% from Rs 172.6 crore in Q1 2025. Profit after tax (PAT) for the quarter stood at Rs 60.7 crore, marking a 21% increase over Q1FY25 and a 109% surge from Rs 29 crore in Q2 2024. The scrip declined 0.84% to Rs 4,624 on the BSE.
Top